[ad_1]
Al-Marsad Journal – SPA: The World Health Organization recommended the use of a treatment combining two types of monoclonal antibodies, a mixture of kazerifimab and imdivimab, developed by the American company Regeneron and the Swiss Roche , to treat a specific group of Covid-19 Patients, after studies have confirmed its effectiveness in treating those most at risk for severe infections and reducing the risk of death, as well as for the treatment of patients with severe infections. severe immune response to resistance to the virus, immunocompromised disease and the elderly.
The organization stressed that this treatment reduces the risk of death or hospitalization during the duration of the symptoms. Especially people who haven’t developed natural antibodies.
The organization announced in a statement the limited supply of the drug and its high price, calling on its producers to increase production.
She referred to the negotiations with Roche regarding the reduction of the price or the donation of a certain number of doses. He also called on drug development companies to deliver new products and treatment options better suited to needs around the world, including middle and low-income countries.
Source link
